Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiniferatoxin for moderate to severe knee osteoarthritis pain
NCT03542838Phase 1Completed
- Sponsor
- Sorrento Therapeutics
- Start
- Jul 2018
- Primary completion
- Apr 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of resiniferatoxin in osteoarthritis (OA) (6 arms), sponsored by Sorrento Therapeutics. Primary endpoint: Safety measurement at 52 weeks. Started Jul 2018; status: completed.
02
Drugs
resiniferatoxin
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03542838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542838.